Infiltrating pancreatic ductal adenocarcinoma (PDAC) is one of the most fatal human malignancies, with an overall five-year survival rate of less than five percent. The high mortality rate associated w/ith PDAC is primarily due to the late stage at which disease is diagnosed and the resistance of pancreatic cancer to traditional chemotherapy and radiotherapy treatment approaches. These observations highlight the critical need for early detection of pancreatic neoplasia at a stage where surgical resection can be curative. The major goal of this proposal will be to use state-of-the-art mass spectrometry and genetically engineered mouse models representing preinvasive or early, organ-confined stages of pancreatic neoplasia to identify a comprehensive set of biomarkers that can be used in combination to prospectively diagnose early neoplasic disease in humans.
In Aim 1, we will identify serum biomarkers in genetically inbred mice that express an activated allele of Kras (KrasG12D) in the pancreatic ductal epithelium and in mice with KrasG12D expressed on a p16lnk4a- or p53-deficient background. Constitutive activation of KRAS is observed in over 90% of PDAC cases and it likely represents one of the earliest genetic lesions in pancreatic cancer.
Aim 2 will utilize newly-derived pancreatic ductal cell lines from the same animal models described in Aim 1 to characterize the complete spectrum of changes that occur in the cell-surface proteome and in the secretome as neoplasia progresses from preinvasive lesions to fully metastatic disease.
In Aim 3, we will utilize histology-guided MALDI-TOF MS tissue profiling to identify biomarkers associated with early-stage pancreatic neoplasia using pancreatic tissue from the animal models. From these results, we expect to compile a comprehensive set of biomarkers for detection of early-stage pancreatic cancer. Finally, in Aim 4, we will test the specificity and sensitivity of the early-stage biomarkers identified in the murine system for their ability to diagnose pancreatic neoplasia using human serum samples collected from healthy donors and cases representing chronic pancreatitis and PDAC. The goal of these studies will be the development of an antibody-based diagnostic assay that can be used to screen high-risk patients for pancreatic cancer.

Public Health Relevance

Pancreatic cancer is the fourth leading cause of cancer death, accounting for approximately 33,000 deaths annually in the United States. Surgical resection ofthe tumor remains the best treatment option but this is often not possible given the advanced stage at initial diagnosis. The primary goal of this project is to use genetically engineered mouse models of early-stage pancreatic neoplasia to derive a comprehensive set of serum biomarkers that can be used to diagnose early-stage pancreatic cancer in humans.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Alabama Birmingham
United States
Zip Code
Tiriac, Hervé; Belleau, Pascal; Engle, Dannielle D et al. (2018) Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. Cancer Discov 8:1112-1129
Tiriac, Herve; Bucobo, Juan Carlos; Tzimas, Demetrios et al. (2018) Successful creation of pancreatic cancer organoids by means of EUS-guided fine-needle biopsy sampling for personalized cancer treatment. Gastrointest Endosc 87:1474-1480
Carlson, Marjorie; Watson, Adrienne L; Anderson, Leah et al. (2017) Multiphoton fluorescence lifetime imaging of chemotherapy distribution in solid tumors. J Biomed Opt 22:1-9
Öhlund, Daniel; Handly-Santana, Abram; Biffi, Giulia et al. (2017) Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J Exp Med 214:579-596
Zhong, Yi; Macgregor-Das, Anne; Saunders, Tyler et al. (2017) Mutant p53 Together with TGF? Signaling Influence Organ-Specific Hematogenous Colonization Patterns of Pancreatic Cancer. Clin Cancer Res 23:1607-1620
Contreras, Carlo M; Lin, Chee Paul; Oster, Robert A et al. (2017) Increased pancreatic cancer survival with greater lymph node retrieval in the National Cancer Data Base. Am J Surg 214:442-449
Roe, Jae-Seok; Hwang, Chang-Il; Somerville, Tim D D et al. (2017) Enhancer Reprogramming Promotes Pancreatic Cancer Metastasis. Cell 170:875-888.e20
Chio, Iok In Christine; Tuveson, David A (2017) ROS in Cancer: The Burning Question. Trends Mol Med 23:411-429
Li, Yonghe; Oliver, Patsy G; Lu, Wenyan et al. (2017) SRI36160 is a specific inhibitor of Wnt/?-catenin signaling in human pancreatic and colorectal cancer cells. Cancer Lett 389:41-48
Feigin, Michael E; Garvin, Tyler; Bailey, Peter et al. (2017) Recurrent noncoding regulatory mutations in pancreatic ductal adenocarcinoma. Nat Genet 49:825-833

Showing the most recent 10 out of 173 publications